

GO-PRACTICE - Study of the conditions of use of golimumab and its impact, in current practice, in patients with chronic inflammatory rheumatism.

Head :LEVY-BACHELOT Laurie, MSD France
Gouyette Najat, MSD France

Last update : 10/19/2017 | Version : 1 | ID : 73342

General	
Identification	
Detailed name	Study of the conditions of use of golimumab and its impact, in current practice, in patients with chronic inflammatory rheumatism.
Sign or acronym	GO-PRACTICE
General Aspects	
Medical area	Rheumatology
Pathology (details)	Rheumatoid arthritis, ankylosing spondylitis and rheumatic psoriasis
Scientific investigator(s) (Contact)	
Name of the director	LEVY-BACHELOT
Surname	Laurie
Address	34 avenue Léonard de Vinci, Courbevoie
Phone	01 80 46 41 98
Email	laurie.levy-bachelot@merck.com
Unit	MSD France
Name of the director	Gouyette
Surname	Najat
Unit	MSD France
Collaborations	
Funding	
Funding status	Private

Governance of the database

Sponsor(s) or organisation(s) responsible MSD France

Organisation status Private

Presence of scientific or steering committees Yes

Additional contact**Main features****Type of database**

Type of database Study databases

Study databases (details) Cohort study

Database objective

Main objective To evaluate the maintenance of golimumab therapy 24 months after initial prescription in adult patients with chronic inflammatory rheumatism in clinical practice in France
The primary endpoint is the total percentage of patients who maintained treatment with golimumab two years after the initial prescription.

Inclusion criteria**Inclusion:**

1. Patients aged 18 years or older.
2. Patients who gave oral consent to participate after receiving oral and written information about the study.
3. Patients with a diagnosis of chronic inflammatory rheumatism.
4. Patients with an initial hospital prescription of golimumab but not yet having initiated treatment with golimumab.
5. Patients able to understand and complete the self-evaluation questionnaires

Non-inclusion:

1. Patients previously treated with golimumab and discontinuing treatment prior to inclusion.
2. Patients who participated in previous golimumab trials
3. Patients who had already begun treatment with golimumab prior to inclusion and were receiving

treatment at the time of inclusion.
 4. Patients with pathologies or conditions that, according to the investigator, would limit the patient's ability to participate fully in the study or to meet all the requirements of the study;

Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Pathology	M05-M14 - Inflammatory polyarthropathies
Gender	Male Woman
Geography area	National
Detail of the geography area	No details available
Data collection	
Dates	
Size of the database	
Size of the database (number of individuals)	[500-1000[individuals
Details of the number of individuals	750 included
Data	
Database activity	Current data collection
Type of data collected	Clinical data Declarative data Paraclinical data Biological data
Clinical data (detail)	Direct physical measures Medical registration
Declarative data (detail)	Paper self-questionnaire
Presence of a biobank	No

Procedures	
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the participant (mail, e-mail, telephone etc.) Monitoring by contact with the referring doctor
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Terms of data access (charter for data provision, format of data, availability delay)	No data access charter
Access to aggregated data	Access not yet planned
Access to individual data	No access